EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy and Safety of Neoadjuvant Dual HER2-Targeted Therapy in Older and Younger Patients With HER2-Positive Early Breast Cancer: A Real-World Retrospective Analysis

Lok-Sze Joyce Au, Yu-Ning Zhang, Kary Yeung, Ka-Long Cheung, Li-Yu Holly Hou, Mai-Yee Luk, Ching-Yu Roland Leung, Wing-Lok Chan

Clinical Breast Cancer · 2026

DOI: 10.1016/j.clbc.2026.01.007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Breast Cancer, 2026. Verfasst von Lok-Sze Joyce Au und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Oncology, Queen Mary Hospital, Hong Kong SAR, China. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Breast Neoplasms, Neoadjuvant Therapy, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Neoadjuvant chemotherapy combined with dual HER2-targeted therapy improves pathological complete response (pCR) rates in early-stage HER2-positive breast cancer. However, data on its efficacy and tolerability in older adults remain limited. OBJECTIVE: To evaluate the efficacy, toxicity, and survival outcomes of neoadjuvant dual anti-HER2 therapy in older adults with HER2-positive early breast cancer. METHODS: This retrospective cohort included patients with HER2-positive early breast cancer treated with neoadjuvant dual anti-HER2 therapy at Queen Mary Hospital, Hong Kong, between January 2017 and December 2023. Patients were stratified by age (< 65 vs. ≥ 65 years). The primary outcome was pCR. Multivariable logistic regression identified predictors of pCR. Progression-free survival (PFS) was assessed using the Kaplan-Meier method with log-rank testing. Treatment-related toxicities (TRT) were graded according to CTCAE v5.0. RESULTS: A total of 227 patients were included, 43 (18.9%) were aged ≥ 65 years. The pCR rate was 51.2% in older patients and 62.0% in younger patients (P = .194). Higher clinical T-stage was significantly associated with lower pCR (OR = 0.25, 95% CI, 0.06-0.67, P = .02). Older patients experienced more grade ≥ 3 TRT (55.8% vs. 28.3%, P < .001), with neutropenia (32.6% vs. 12.0%) and diarrhoea (16.3% vs. 7.1%) being most common. Unplanned hospitalisations were more frequent (14.0% vs. 4.9%, P = .001). No significant difference in PFS was observed (P = .21). Five-year PFS rates were 87.4% (95% CI, 76.3%-100%) in older patients and 95.2% (95% CI, 92.0-98.6%) in younger patients. CONCLUSION: Older patients achieved pCR and PFS comparable to younger counterparts but experienced higher toxicity and hospitalisation rates. Age-specific and de-escalation strategies warrant further study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erb-b2 Receptor Tyrosine KinasesBreast NeoplasmsNeoadjuvant TherapyAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleRetrospective StudiesAgedPathologic Complete ResponseMiddle AgedAge FactorsTrastuzumabAdultAntibodies, Monoclonal, HumanizedLapatinibNeoplasm Staging

Stichwörter der Autor:innen

Geriatric oncologyHER2-positive breast cancerNeoadjuvant therapyPathological complete responsePertuzumab

Substanzen

Erb-b2 Receptor Tyrosine KinasesERBB2 protein, humanTrastuzumabpertuzumabAntibodies, Monoclonal, HumanizedLapatinib

Autor:innen und Institutionen

  • Department of Clinical Oncology, Queen Mary Hospital, Hong Kong SAR, China.
  • Department of Clinical Oncology, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
  • School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
  • Department of Medicine, Queen Mary Hospital, Hong Kong SAR, China.
  • Department of Clinical Oncology, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China. Electronic address: winglok@hku.hk.

Zitieren

APA

Au, L. J., Zhang, Y. N., Yeung, K., Cheung, K. L., Hou, L. H., Luk, M. Y., Leung, C. R., & Chan, W. L. (2026). Efficacy and Safety of Neoadjuvant Dual HER2-Targeted Therapy in Older and Younger Patients With HER2-Positive Early Breast Cancer: A Real-World Retrospective Analysis. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2026.01.007

Vancouver

Au LJ, Zhang YN, Yeung K, Cheung KL, Hou LH, Luk MY, et al. Efficacy and Safety of Neoadjuvant Dual HER2-Targeted Therapy in Older and Younger Patients With HER2-Positive Early Breast Cancer: A Real-World Retrospective Analysis. Clinical Breast Cancer. 2026. doi:10.1016/j.clbc.2026.01.007

BibTeX
@article{Au2026,
  author = {Au, Lok-Sze Joyce and Zhang, Yu-Ning and Yeung, Kary and Cheung, Ka-Long and Hou, Li-Yu Holly and Luk, Mai-Yee and Leung, Ching-Yu Roland and Chan, Wing-Lok},
  title = {Efficacy and Safety of Neoadjuvant Dual HER2-Targeted Therapy in Older and Younger Patients With HER2-Positive Early Breast Cancer: A Real-World Retrospective Analysis},
  journal = {Clinical Breast Cancer},
  year = {2026},
  doi = {10.1016/j.clbc.2026.01.007}
}
Kostenlos starten →